{"id":34117,"date":"2025-03-24T11:27:33","date_gmt":"2025-03-24T15:27:33","guid":{"rendered":"https:\/\/avalere.com\/?p=34117"},"modified":"2025-03-24T13:50:14","modified_gmt":"2025-03-24T17:50:14","slug":"disease-registries-offer-solutions-in-rare-disease","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/insights\/disease-registries-offer-solutions-in-rare-disease","title":{"rendered":"Disease Registries Offer Solutions in Rare Disease"},"content":{"rendered":"

Components and Considerations for Disease Registries<\/strong><\/p>\n

Disease registries are tools to collect, store, retrieve, analyze, and disseminate clinical and outcomes data for a predefined patient population. Registries can be sponsored by professional medical societies, patient advocacy organizations, government agencies, non-profit organizations, private companies, or healthcare facilities. While there is no centralized source that lists all registries available in the United States, the National Institutes of Health<\/a> and National Organization for Rare Disorders<\/a> have a comprehensive list of registries for both prevalent and rare diseases. Over forty of them were designed specifically for rare and ultra-rare diseases.<\/p>\n

Establishing a disease registry is a multi-step process that requires a clear purpose and scope, assembly of a multidisciplinary team, a thoughtfully designed data collection, establishing governance and oversight plan, and analysis and dissemination of findings. The patient population to be enrolled in the registry must be clearly defined before enrollment begins. Participants may enter a registry during a normal course of care such as through newborn screening<\/a> programs, through recruitment into a research study, or through voluntarily participation in a self-identified registry.<\/p>\n

Disease registries serve many purposes and have the potential to support researchers and manufacturers with drug development programs, inform the design of interventional and observational studies, enhance understanding of the natural history of a disease, and support the selection of appropriate endpoints and biomarkers that are associated with clinically meaningful outcomes. Furthermore, registries provide additional insights into an intervention (e.g., drug, device) and its efficacy and safety in populations underrepresented in clinical trials.<\/p>\n

Multiple stakeholders can be involved in establishing disease registries, including regulatory agencies, patient advocacy groups, clinicians, key opinion leaders, scientists, payers, patients, and their caregivers. Collaboration between these stakeholders can drive not only research and development of new treatments but also lead to public policy changes and promote access to treatments. Various organizations around the world, including the National Organization for Rare Disorders<\/a> in the United States recognize the challenges associated with data collection and clinical trial recruitment for rare and ultra-rare diseases, and have thus become advisors and supporters of rare disease registries.<\/p>\n

Registries for Rare and Ultra-Rare Disease<\/strong><\/p>\n

While drug developers in the rare and ultra-rare disease space<\/a> face many unique challenges, registries can help address some of them (Table 1).<\/p>\n

Table 1. Registry Benefits for Rare and Ultra-Rare Diseases<\/strong><\/p>\n

 <\/p>\n\n<\/thead>\n\n\n\n\n\n
Disease heterogeneity<\/td>\nRare diseases, even within the same category (e.g., leukodystrophies, mitochondrial disorders), vary greatly in their clinical presentation, severity, progression, prior exposure to different treatments, etc. Registries can help aggregate data on genotypically similar but phenotypically different conditions.<\/td>\n<\/tr>\n
Disease natural history<\/td>\nRegistries provide consistent updates on the patient\u2019s status throughout a predefined schedule that offers consistent, high-quality data on the natural progression of the disease. In addition, as more treatments extending the life span of patients with rare diseases become available, registries provide opportunities to learn more about the disease trajectory.<\/td>\n<\/tr>\n
Establish the patient base for small, geographically dispersed populations<\/td>\nData is typically collected in multiple institutions and geographic regions, providing comprehensive information on patients with rare and ultra-rare diseases who are dispersed throughout the country. Registries also support the shaping of the patient base for evaluating treatments, devices, and other medical interventions for clinical trial development programs.<\/td>\n<\/tr>\n
Support development of biomarkers and clinically meaningful endpoints<\/td>\nRegistries may involve the collection and storage of biospecimens that can be further studied as potential biomarkers for the establishment of clinically meaningful endpoints. Considering the lack of knowledge about many rare and ultra-rare conditions coupled with the lack of established and approved biomarkers, registries can help manufacturers overcome some of the barriers associated with limited data availability and limited knowledge.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Although registries provide significant opportunities, they do face headwinds:<\/p>\n